Chinese Hepatolgy ›› 2020, Vol. 25 ›› Issue (2): 123-127.

• Viral Hepatitis • Previous Articles     Next Articles

Clinical profiles and treatment patterns of patients with HBV-related liver cirrhosis

KONG Yuan-yuan1, WEI Wei1, SHAN Shan2, MA Hong2, OU Xiao-juan2, XU Xiao-yuan3, DUAN Zhong-ping4, HOU Jin-lin5, WEI Lai6, YOU Hong2, JIA Ji-dong2, CR-HepB Group   

  1. 1. Clinical Epidemiology and EBM Unit, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing 100050, China;
    2. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;
    3. Peking University First Hospital, Beijing, 100034, China;
    4. Beijing YouAn Hospital, Capital Medical University, Beijing, 100069, China;
    5. Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China;
    6. Beijing Tsinghua Changguang Hospital, Beijing 102218, China
  • Received:2019-11-14 Online:2020-02-29 Published:2020-03-26
  • Contact: JIA Ji-dong, E-mail: jia_jd@ccmu.edu.cn

PDF (PC)

696

Abstract: Objective To analyze the clinical profiles and treatment patterns of patients with hepatitis B virus (HBV)-related cirrhosis in real-world clinical setting in China. Methods The demographic, clinical and treatment data were analyzed from enrolled patients in China Registry of Hepatitis B. Results A total of 5263 patients with HBV-related liver cirrhosis were included in the study, including 2013 (38.2%) patients with compensated status, 2752 patients (52.3%) with decompensated status and 498 patients (9.5%) unspecified. From 2010 to 2019, the proportion of patients ≥ 50 years old in those diagnosed with cirrhosis increased from 45.6% to 57.9%, the hepatitis B envelope antigen (HBeAg) positive rate decreased from 47.4% to 35.8%, and the use of the first-line antiviral drugs (entecavir or tenofovir) increased from 41.9% to 92.8%. Conclusion The real-world study demonstrated that the age of patients with diagnosis of cirrhosis gradually increased, the HBeAg positive rate gradually decreased, and the use of first-line antiviral drugs dramatically increased.

Key words: Chronic hepatitis B, Liver cirrhosis, Antiviral therapy, Real-world study